ICH - Safety Guidelines S1A – S9
S1A Guideline on the Need for Carcinogenicity Studies
S1B Testing for Carcinogenicity of Pharmaceuticals
S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals
S2(R1) Guidance on Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use
S3A Note for Guidance on Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies
Pharmacokinetics: Guidance for Repeated Dose Tissue Distribution Studies
S4 Duration of Chronic Toxicity Testing in Animals (Rodent and Non Rodent Toxicity Testing)
S5(R2) Detection of Toxicity to Reproduction for Medicinal Products & Toxicity to Male Fertility
S6(R1) Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals
S7A Safety Pharmacology Studies For Human Pharmaceuticals
S7B The Non-Clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) By Human Pharmaceuticals
S8 Immunotoxicity Studies for Human Pharmaceuticals
S9 Nonclinical Evaluation for Anticancer Pharmaceuticals
